tiprankstipranks
Trending News
More News >

Zelira Therapeutics Strengthens Financial Position and Advances Product Development

Story Highlights
Zelira Therapeutics Strengthens Financial Position and Advances Product Development

Don’t Miss TipRanks’ Half-Year Sale

Zelira Therapeutics ( (AU:ZLD) ) just unveiled an update.

Zelira Therapeutics has enhanced its financial flexibility by receiving a $1.15 million R&D Tax Incentive refund and establishing a $1 million At-the-Market funding facility. These financial moves support its ongoing development programs, including preparations for the FDA clinical trial of HOPE® 1. The company also completed the full conversion of US$3.25 million convertible notes into equity, strengthening its capital structure. The development of capsule formulations for HOPE® and Zenivol® using Zyraydi™ technology is on track for completion in mid to late 2025, aligning with Zelira’s strategy to enhance product consistency and market readiness.

More about Zelira Therapeutics

Zelira Therapeutics Ltd is a global leader in the development and commercialization of clinically validated cannabinoid-based medicines. The company focuses on advancing its pipeline of cannabinoid-based therapies, with a strong emphasis on clinical validation and market readiness.

YTD Price Performance: -21.32%

Average Trading Volume: 279

Technical Sentiment Signal: Buy

Current Market Cap: $2.66M

See more insights into ZLD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1